Atea plunges after COVID-19 treatment fails to help patients in study
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Atea Pharmaceuticals (AVIR) Strong Sell-Off 'Premature' - William Blair
October 19, 2021 10:55 AM EDTWilliam Blair analyst Tim Lugo reiterated an Outperform rating and {REMOVEPT} price target on Atea Pharmaceuticals (NASDAQ: AVIR) amid today's sell-off, calling it "premature."
The analyst commented, "While the top-line miss in the Phase II MOONSONG study is a setback for Atea, we... More
